BioLife
Financials
2022 Fiscal Year Annual Revenue
$30.17 Billion
2022 Fiscal Year Gross Profit
$20.79 Billion
2022 Fiscal Year Annual Net Income
$3.55 Billion
2022 Fiscal Year Gross Profit Growth
2.67%
2022 Number of U.S. Stores
180
Credit Rating
Leases are guaranteed by Takeda Pharmaceuticals U.S.A., Inc, which is a wholly-owned subsidiary of Takeda Pharmaceutical Co. Ltd., which is S&P Rated: Investment Grade BBB+ (Long-Term) A-2 (Short-Term)
BioLife
BioLife Plasma Services is a leading company for high-quality plasma collection. A part of a global biopharmaceutical company, Takeda Pharmaceutical Compnay Limited (NYSE:TAK), BioLife continues to use high-quality plasma for the benefit of those in need. The financials and credit ratings presented are representative of the consolidated results of Takeda Pharmaceutical Company, which is BioLife Plasma Services’s parent entity.